Shoulder Innovations filings document a Delaware medical technology issuer focused on shoulder arthroplasty implants and related surgical-care technologies. Form 8-K reports cover operating results, Regulation FD disclosures, product-launch announcements, FDA-cleared indications, strategic partnership announcements, and material agreements tied to corporate facilities.
Governance filings include the definitive proxy statement for the annual meeting, director elections, board committee matters, non-employee director compensation, and stockholder voting procedures. Current reports also record director appointments, resignations, independence determinations, indemnification arrangements and other corporate-governance events.
Shoulder Innovations, Inc. Chief Operating Officer Matthew Fraser Ahearn exercised stock options to acquire a total of 21,664 shares of common stock on April 20, 2026, at exercise prices of $2.8620 and $2.4804 per share. Following these exercises, he directly holds 286,765 common shares. No open-market sales were reported in this filing.
Shoulder Innovations, Inc. entered into a new long-term lease for a purpose-built corporate headquarters. The company agreed with Ventura Office Park Lot #8, LLC to have a roughly 15,200-square-foot office and warehouse building constructed in Byron Center, Michigan.
The lease runs for an initial 10-year term, with two additional five-year extension options and certain expansion rights. Estimated aggregate rent over the initial term is about $4.4 million. The company has paid a $33.0 thousand security deposit and a further $0.5 million down payment toward construction costs. Possession is expected around the fourth quarter of 2027, after a certificate of occupancy is issued and the landlord substantially completes its work.
SHOULDER INNOVATIONS, INC. Chief Financial Officer Jeffrey S. Points increased his stake through option exercises and a share purchase. On March 13, 2026, he exercised stock options to acquire 13,264 shares of common stock at $2.4804 per share, converting a derivative position into stock. He also made an open-market purchase of 2,000 common shares at $15.00 per share the same day. Following these transactions, he holds 70,785 common shares directly and 50 shares indirectly held by his son. The exercised option was part of a grant that vests in 31 equal monthly increments beginning on March 31, 2025.
Shoulder Innovations director Paul Buckman exercised stock options to acquire 45,606 shares of Common Stock on March 13, 2026. He exercised 19,401 options at $2.4804 per share and 26,205 options at $2.0988 per share. To cover tax obligations, 7,006 shares were withheld in transactions priced at $14.62 and $14.82 per share. After these compensation-related transactions, Buckman directly holds 58,704 shares of Shoulder Innovations common stock.
Shoulder Innovations director Richard Buchholz reported an open-market purchase of 1,000 shares of common stock at $14.84 per share. This buy increased his direct ownership to 13,666 common shares. The transaction was classified as a standard open-market purchase, indicating he used personal capital to add to his position.
SHOULDER INNOVATIONS, INC. CEO & Executive Chairman Robert Joseph Ball bought 2,200 shares of Common Stock in an open-market transaction. The weighted average purchase price was $15.1782 per share, with individual trades ranging from $14.80 to $15.50. After this purchase, he directly owns 278,866 shares.
Shoulder Innovations, Inc. files its annual report describing a commercial-stage medical technology business focused solely on shoulder surgical care. The company sells advanced anatomic and reverse shoulder implant systems, its AI-enabled ProVoyance planning software, and a two-tray instrument platform designed to simplify procedures, especially in outpatient surgery centers.
Management estimates about 250,000 U.S. shoulder arthroplasty procedures in 2025, an approximately $1.7 billion market, and a global opportunity of about $2.7 billion growing roughly 11% annually through 2029. Its implants have been used in more than 17,500 procedures, with clinical studies showing long-term durability of the InSet Glenoid design.
The report highlights a specialized sales model targeting roughly 1,800 high-volume U.S. surgeons, strong adoption of ProVoyance in virtually all Shoulder Innovations cases, and a 50% increase in procedure volume from 2024 to 2025. As of March 3, 2026, the company had 20,647,526 common shares outstanding and continues to expand its product pipeline, including metal-sensitive implants, fracture and revision solutions, and a developing shoulder-specific robotics platform.
Shoulder Innovations reported strong growth but widening losses for the fourth quarter and full year 2025, and announced that director Michael Carusi will not stand for re-election at the 2026 annual meeting, a decision the company says is not due to any disagreement with management or the board.
Fourth quarter net revenue rose 65% to $14.4 million, while full-year net revenue increased 50% to $47.3 million, driven by higher implant system volumes and new customers. Gross margin remained high at about 77% for both the quarter and the year, reflecting attractive product economics.
Despite this growth, operating expenses climbed sharply, leading to a 2025 operating loss of $26.3 million and a net loss of $40.4 million. The company ended 2025 with $124.3 million in cash, cash equivalents and marketable securities, and issued 2026 net revenue guidance of $62 million to $65 million, implying growth of roughly 31% to 37% over 2025.
SHOULDER INNOVATIONS, INC. director Andrew Hykes filed an initial Form 3 to report his beneficial ownership as a company insider. The filing lists him as a director and does not show any share purchases, sales, or other transactions in this excerpt.
Shoulder Innovations, Inc. reported that on February 26, 2026, Geoff Pardo resigned as a Class I director, a member of the Compensation Committee, and Chair of the Nominating and Corporate Governance Committee, effective immediately. The company stated his resignation was not due to any disagreement with management or the Board.
On the same date, the Board appointed Andrew (Drew) Hykes, age 53, as a Class I director and member of the Compensation Committee, also effective immediately. He will receive standard non-employee director compensation and enter into the company’s standard indemnification agreement. The Board determined he is an independent director and meets New York Stock Exchange and Exchange Act requirements for Compensation Committee service.
The filing and accompanying press release highlight Mr. Hykes’s more than 25 years of medical device and healthcare experience, including leadership roles at Okami Medical, Inari Medical, Sequent Medical, and Medtronic, as well as his banking background and business degrees from the University of Wisconsin–Madison and Harvard Business School.